Inloggad som:
Prevent-A-CaLL
Är du som patient intresserad av mer information om en studie, kontakta din behandlande läkare.
Prevent-A-CaLL
Short-term combined acalabrutinib and venetoclax treatment of newly diagnosed patients with CLL at high risk of infection and/or early treatment who do not fulfil IWCLL treatment criteria for treatmnet. A randomized study with extensive immune phenotyping
Short-term Combined Acalabrutinib and Venetoclax Treatment of Newly Diagnosed Patients With CLL at High Risk of Infection and/or Early Treatment, Who do Not Fulfil IWCLL Treatment Criteria.
PLACEHOLDER
Mer information om studien för vårdgivare
Studien ändrades senast av: Anita Björk (2023-09-11)